

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5270566

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
GABRIEL NUSSBAUM	12/12/2017
AMNON HOFFMAN	12/12/2017
CHAIM GILON	12/12/2017
RECEIVING PARTY DATA	
Name:	YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
Street Address:	HI TECH PARK, EDMOND J. SAFRA CAMPUS, GIVAT RAM, P.O. BOX 39135
City:	JERUSALEM
State/Country:	ISRAEL
Postal Code:	91390
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16307841
CORRESPONDENCE DATA	
Fax Number:	(202)533-9187
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(202) 467-8800
Email:	lmelliott@vorys.com
Correspondent Name:	VORYS, SATER, SEYMOUR AND PEASE LLP
Address Line 1:	1909 K ST., NW
Address Line 2:	9TH FLOOR
Address Line 4:	WASHINGTON, D.C. 20006-1152
ATTORNEY DOCKET NUMBER:	068717-000123
NAME OF SUBMITTER:	ARI G. ZYT CER
SIGNATURE:	/Ari G. Zytcer/
DATE SIGNED:	12/06/2018
Total Attachments: 1	
source=PCT_Assign_exe#page1.tif	



ASSIGNMENT



For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged I/We the undersigned NUSSBAUM, Gabriel, 63 Derech Beit Lechem, 93229 Jerusalem, Israel; HOFFMAN, Amnon, 22 Anusei Mashad Street, 93784 Jerusalem, Israel; GILON, Chaim, 18 Gelber Street, 96755 Jerusalem, Israel (hereinafter referred to as the Assignor/s) do hereby sell, assign and confirm that prior to June 4, 2017, I/We did irrevocably assign to Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (hereinafter referred to as the assignee) whose full post office address is: Hi Tech Park, Edmond J. Safra Campus, Givat Ram P.O. Box 39135, 91390 Jerusalem, Israel, all my right, title, and interest to my invention entitled:



BACKBONE CYCLIZED INHIBITORY PEPTIDES OF MYELOID DIFFERENTIATION FACTOR 88 (MYD88)

as disclosed in PCT Patent Application No. PCT/IL2017/050621 filed June 4, 2017 claiming priority from U.S. Provisional Patent Application No. 62/346,580 filed June 7, 2016.

NOW, THEREFORE, the said Assignor/s has sold, assigned, transferred and set over to said Assignee, the entire right, title and interest in the PCT and all corresponding national or regional stage applications derived therefrom, including any continuations, divisions, continuations-in-part, reissues, reexaminations, extensions or foreign equivalents thereof, and including the subject matter of all claims which may be obtained therefrom for its own use and benefit, and for the use and benefit of its successors, assigns or other legal representatives, as fully and entirely as the same would have been held and enjoyed by Assignor/s if this Assignment and sale had not been made and all the corresponding right, title, and interest in and to any patent which may issue therefrom.

Signed at Jerusalem this 12 day of December 2017

Gabriel Nussbaum

Amnon Hoffman
(witness)

Signed at JERUSALEM this 12 day of 12 2017

Amnon Hoffman

Chaim Gilon
(witness)

Signed at Jerusalem this 12 day of December 2017

Chaim Gilon

Amnon Hoffman
(witness)